Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (<100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial)

Next Previous
Search
Trial Profile

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (<100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial)

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darunavir (Primary) ; Dolutegravir (Primary) ; Abacavir/dolutegravir/lamivudine; Lamivudine/abacavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms Advanz-4

    • Most Recent Events

    • 22 Feb 2023 Results of substudy evaluating association of gut microbes and recovery of late hiv presenters, presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
    • 16 Feb 2022 Results assessing plasma CMV viral load (VL) by quantitative PCR and CMV-specific IgG/IgM at baseline, presented at the 29th Conference on Retroviruses and Opportunistic Infections.
    • 10 Mar 2021 Primary endpoint (Median CD4 T cell count increase) has not been met as per results presented at the 28th Conference on Retroviruses and Opportunistic Infections.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top